A Phase 3 trial in The Lancet reports that deramiocel, a heart-derived allogeneic cell therapy, slowed functional decline in boys and young men with advanced Duchenne muscular dystrophy (DMD). The HOPE-3 study randomized 106 patients (10 to 22 years old) across 20 U.S. sites to deramiocel or placebo given as blood infusions every three months for one year. After 12 months, the deramiocel group showed slower loss of upper-limb function than placebo, with arm movement decline about 54% less and elbow movement about 65% less. Among participants with existing heart muscle disease, heart function was better preserved with deramiocel, and subgroup analyses suggested less spread of heart scarring. The therapy was generally safe, with no deaths reported. Allergic-type reactions were more common with deramiocel (42%) versus placebo (15%), while most other adverse events were mild to moderate and transient. While the clinical signal is encouraging, the next regulatory step remains tightly watched as the results interface with FDA review considerations for statistical analysis plans and efficacy claims.